Skip to content

Evaluating Mammography Communication Approaches

Evaluating Mammography Communication Approaches

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07228234
Enrollment
1900
Registered
2025-11-14
Start date
2025-11-06
Completion date
2027-11-30
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Focus of This Study is to Identify How Different Approaches to Mammography Communication Affect Skepticism Toward Mammography Evidence

Keywords

Communication, Mammography

Brief summary

This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to experimental conditions which vary whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and vary the presence or absence of information about improvements in breast cancer survivability. In a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions). Primary outcomes include skepticism toward the information presented, and screening intentions.

Detailed description

This is a randomized online experiment testing different methods for communicating about the benefits and harms of breast cancer screening. Participants will be randomly assigned to 1 of 5 experimental conditions, in a 2 x 2 + 1 factorial design, which vary (1) whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and (2) the presence or absence of information about improvements in breast cancer treatment and survivability. In a 5th arm, a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions). Primary outcomes include skepticism toward the information presented, and screening intentions.

Interventions

OTHERHarm/benefit language vs. outcomes that can happen

Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".

OTHERBreast cancer survivability information

Information about improvements over time in the survivability of breast cancer is provided vs. not

OTHERNo intervention

This is the control condition in which only basic information about mammography screening.

Sponsors

University of Colorado, Denver
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Intervention model description

This is a 2 x 2 +1 randomized factorial design. Participants will be randomly assigned to 1 of 5 experimental conditions, which vary (1) whether screening outcomes are referred to as "benefits and harms" vs. "outcomes that can happen with screening", and (2) the presence or absence of information about improvements in breast cancer treatment and survivability. In a 5th arm, a control condition, participants receive basic information about what mammography is (which is also information received in all other conditions).

Eligibility

Sex/Gender
FEMALE
Age
39 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Female, age 39-49

Exclusion criteria

* No history of breast cancer, no known BRCA1/2 gene mutation

Design outcomes

Primary

MeasureTime frameDescription
Skepticism toward the screening messageParticipant experience entails a one-time survey. This outcome is measured in that survey, immediately after participants read information about mammography screening.Skepticism toward the screening message is assessed using the RED scale, consisting of 11 questions each measured on a 7-point Likert scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026